Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,516.86
    -1,739.49 (-3.46%)
     

  • CMC Crypto 200

    1,261.13
    -96.88 (-7.13%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

New Strong Sell Stocks for September 14th

Zacks Equity Research
·1-min read

Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:

AptarGroup, Inc. ATR is a leading global supplier of a broad range of innovative dispensing systems for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. The Zacks Consensus Estimate for its current year earnings has been revised 0.3% downward over the last 30 days.

Fortress Transportation and Infrastructure Investors LLC FTAI is engaged in the owning and acquisition of infrastructure and equipment for leasing. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.

Humanigen, Inc. HGEN is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.

ADVERTISEMENT

Limbach Holdings, Inc. LMB provides building systems. The Zacks Consensus Estimate for its current year earnings has been revised 1.9% downward over the last 30 days.

Mersana Therapeutics, Inc. MRSN is a biotechnology company. The Zacks Consensus Estimate for its current year earnings has been revised 4.2% downward over the last 30 days.

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AptarGroup, Inc. (ATR) : Free Stock Analysis Report
 
Fortress Transportation and Infrastructure Investors LLC (FTAI) : Free Stock Analysis Report
 
Limbach Holdings, Inc. (LMB) : Free Stock Analysis Report
 
KaloBios Pharmaceuticals Inc. (HGEN) : Free Stock Analysis Report
 
Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research